|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验显示文摘背景:以前的血管内超声(intravascular ultrasound,IVUS)试验证实,他汀治疗可减缓或阻止动脉粥样硬化的进展,但是迄今尚无应用动脉粥样斑块体积百分比(percent atheroma volume,PAV)证实粥样硬化消退的确切证据。PAV是最严格的评价病变进展和消退的IVUS测量指标。
目标:评价极高强度他汀治疗是否能逆转IVUS确定的冠状动脉粥样硬化。
设计和地点:于美国、加拿大、欧洲和澳大利亚53个社区和3级保健中心进行前瞻性开标盲法终点试验(A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden,ASTEROID)。应用马达驱动回撤IVUS评价基线和治疗24个月时冠状动脉粥样斑块负荷。每对基线和随访IVUS测量结果均进行盲法分析。
病例:从2002年11月到2003年10月,507例患者有基线IVUS检查结果,并接受至少1个剂量的研究药物。在24个月后,349例患者具有可用于评估的系列IVUS检查结果。
干预:所有患者均接受瑞舒伐他汀40ms/d强化治疗。
主要观测指标:预先设定了两个一级疗效指标:PAV变化和基线最严重病变10min节段动脉粥样斑块体积变化。二级疗效指标为整个动脉标准化总斑块体积的变化。结果:平均(SD)LDL—C水平由基线时的130.4(34.3)ms/dL降至60.8(20.0)ms/扎,平均下降了53.2%(P〈0.001)。平均(SD)HDL-C水平从基线时的43.1(11.1)ms/dL升至49.0(12.6)ms/dL,平均增加了14.7%(P〈0.001)。整个血管PAV平均(SD)变化为-0.98%(3.15%),中位数为-0.79%(97.5%CI,-1.21%~-0.53%)(与基线比较,P〈0.001)。最严重病变10min节段斑块体积平均(SD)变化为-6.1(10.1)mm^3,中位数为-5.6mm^3(97.5%CI,-6.8~-4.0mm^3)(与基线比较,P〈0.001)。总斑块体积变化中位数降低了6.8%,平均减少了-14.7(25.7)mm^3,中位数为-12.5mm^3(95%CI,-15.1~-10.5mm^3)(与基线比较,P〈0.001)。不良事件少见,与其他他汀试验相似。
结论:应用瑞舒伐他汀40ms/d进行极高强度他汀治疗可使LDL-C平均水平达到60.8ms/dL,使HDL—C增加14.7%。这导致所有3个预先设定的IVUS斑块负荷指标均显示动脉粥样硬化消退。因此,将LDL-C降至低于目前指南规定的水平,同时显著提高HDL-C,可以使冠心病患者动脉粥样硬化斑块消退。这些变化对临床预后的影响尚需进一步研究确定。 | Steven E. Nissen Stephen J. Nicholls Ilks Sipahi Peter Libby Joel S. Raichlen Christie M. Ballantyne Jean Davignon Raimund Erbel Jean Charles Fruchart Jean-Claude Tardif Paul Schoenhagen Tim Crowe Valerie Cain Kathy Wolski Marlene Coormastic E. Murat Tuzcu 仝其广(译) 王淑敏(译) 胡大一(校) | 2006 | 美国医学会杂志(中文版)2006，25，4： | 341 |
| 2 | 他汀、高密度脂蛋白胆固醇与冠状动脉粥样硬化消退显示文摘背景:他汀类药物可以降低低密度脂蛋白胆固醇(low—density lipoprotein cholesterol,LDL—C)水平并减缓冠状动脉粥样硬化的进展。然而,对于他汀类药物所致高密度脂蛋白胆固醇(high—density lipoprotein cholesterol,HDL—C)变化与疾病进展的关系,目前仍无相关数据描述。目的:了解LDL—C和HDL—C水平变化与动脉粥样硬化的相互关系。设计、地点及患者:对4项前瞻性随机试验(1999~2005年在美国、北美、欧洲和澳大利亚进行)的原始数据进行事后分析。其中1455例经血管造影证实的冠心病患者在接受他汀治疗(18个月或24个月)时进行了系列血管内超声扫描。所有超声分析均在相同的核心实验室中进行。主要观测指标:脂蛋白水平变化与冠状动脉粥样斑块体积的相互关系。结果:他汀治疗期间,LDL—C平均(SD)水平从124.0(38.3)mg,/dL(3.2[0.99]mmol/L)降至87.5(28.8)mg,/dL(2.3[0.75]mmol/L)(下降23.5%;P〈0.001),HDL—C水平从42.5(11.0)mg/dL(1.1[0.28]mmol/L)升至45.1(11.4)mg/dL(1.2[0.29]mmol/L)(上升7.5%;P〈0.001)。LDL—C与HDL—C比值从平均(SD)3.0(1.1)降至2.1(0.9)(下降26.7%;P〈0.001)。这些变化同时伴随平均(SD)百分粥样斑块体积的增加(从39.7%[9.8%]增至40.1%[9.7%])(增加0.5%[3.9%];P=0.001)以及平均(SD)总粥样斑块体积的减小(2.4[23.6]mm^3;P〈0.001)。在单变量分析中,LDL—C、总胆固醇、非HDL胆固醇、载脂蛋白B以及载脂蛋白B与载脂蛋白A-1比值平均水平和治疗引起的变化与动脉粥样硬化进展速率显著相关,而治疗所致HDL—C变化则与动脉粥样斑块体积负相关。在多变量分析中,平均LDL—C水平(β系数,0.11[95%可信区间,0.07~0.15])以及HDL—C升高(β系数,-0.26[95%可信区间,-0.41--0.10])依然为动脉粥样硬化消退的独立预测因子。动脉硬化显著消退(动脉粥样斑块体积减少≥5%)见于治疗期间LDL—C水平低于均值(87.5mg/dL)和HDL—C升高百分比大于均值(7.5%;P〈0.001)的患者。临床事件的发生未见显著差异。结论:在LDL—C显著降低以及HDL上升〉7.5%时,他汀治疗与冠状动脉粥样硬化消退相关。这些结果提示他汀治疗的获益源自致动脉粥样硬化脂蛋白的降低以及HDL.C的升高。尽管血脂水平的这些变化与动脉粥样硬化消退相关,但是后者是否可以转化为临床事件的显著减少,并改善临床预后仍有待进一步研究确定。 | Stephen J. Nicholls, MBBS, PhD E. Murat Tuzcu, MD IIke Sipahi, MD Adam W. Grasso, MD Paul Schoenhagen, MD Tingfei Hu, MS Kathy Wolski, MPH Tim Crowe, BS Milind Y. Desai, MD Stanley L. Hazen, MD, PhD Samir R. Kapadia, MD Steven E. Nissen, MD 李呈亿(译) | 2007 | 美国医学会杂志(中文版)2007，26，3： | 48 |
| 3 | Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis显示文摘AIM: To determine the eff icacy of tacrolimus on clinical status, histopathological status and biochemical markers in patients with steroid refractory autoimmune hepatitis (AIH). METHODS: Retrospectively, clinical parameters, biochemistry and histology were obtained from patient records. RESULTS: Nine patients [8 females/1 male, median age 32 (range 16-64) years] were identified to have received tacrolimus for a median duration of 18 (12-37) mo. Before initiation of tacrolimus treatment the patients were maintained on a prednisolone dose of 20 mg daily (range 20-80 mg/d), which was tapered to 7.5 (5-12.5) mg/d (P = 0.004). Alanine aminotransferase and immunoglobulin-G concentrations decreased from 154 (100-475) to 47(22-61) U/L (P = 0.007), and from 16 (10-30.2) to 14.5 (8.4-20) g/L (P = 0.032), respectively. All patients showed improvement of the liver inflammatory activity, as determined by the Ishak score (P = 0.016), while the degree of f ibrosis tended to decrease (P = 0.049). CONCLUSION: The use of low dose tacrolimus can lead to biochemical and histologic improvement of inflammation with no progression of the stage of f ibrosis in patients with steroid refractory AIH. Low dose tacrolimus therapy also allows substantial reduction of prednisone dose. | Fin Stolze Larsen Ben Vainer Martin Eefsen Peter Nissen Bjerring Bent Adel Hansen | 2007 | World Journal of Gastroenterology2007，13，23： | 15 |
| 4 | 罗格列酮对心肌梗死风险和心血管性死亡风险的影响显示文摘背景:罗格列酮被广泛应用于治疗2型糖尿病,但其对心血管疾病发病率和心血管性死亡率的影响尚未确定。方法:对已发表的文献、FDA网站和由制药厂(GlaxoSmithKline) | Nissen S.E. Wolski K. 刘少伟 | 2007 | 世界核心医学期刊文摘(心脏病学分册)2007，，10： | 14 |
| 5 | Animal models of pancreatitis: Can it be translated to human pain study?显示文摘Chronic pancreatitis affects many individuals around the world,and the study of the underlying mechanisms leading to better treatment possibilities are important tasks.Therefore,animal models are needed to illustrate the basic study of pancreatitis.Recently,animal models of acute and chronic pancreatitis have been thoroughly reviewed,but few reviews address the important aspect on the translation of animal studies to human studies.It is well known that pancreatitis is associated with epigastric pain,but the understanding regarding to mechanisms and appropriate treatment of this pain is still unclear.Using animal models to study pancreatitis associated visceral pain is difficult,however,these types of models are a unique way to reveal the mechanisms behind pancreatitis associated visceral pain.In this review,the animal models of acute,chronic and un-common pancreatitis are briefly outlined and animal models related to pancreatitis associated visceral pain are also addressed. | Jing-Bo Zhao Dong-Hua Liao Thomas Dahl Nissen | 2013 | World Journal of Gastroenterology2013，19，42： | 6 |
| 6 | Cytomegalovirus in inflammatory bowel disease: Asystematic review显示文摘AIM: To identify definitions of cytomegalovirus(CMV) infection and intestinal disease, in inflammatory bowel disease(IBD), to determine the prevalence associated with these definitions.METHODS: We conducted a systematic review and interrogated Pub Med, EMBASE and Cochrane for literature on prevalence and diagnostics of CMV infection and intestinal disease in IBD patients. As medical headings we used 'cytomegalovirus' OR 'CMV' OR 'cytomegalo virus' AND 'inflammatory bowel disease' OR 'IBD' OR 'ulcerative colitis' OR 'colitis ulcerosa' OR 'Crohn's disease'. Both Me SH-terms and free searches were performed. We included all types of English-language(clinical) trials concerning diagnostics and prevalence of CMV in IBD.RESULTS: The search strategy identified 924 citations, and 52 articles were eligible for inclusion. We identified 21 different definitions for CMV infection, 8 definitions for CMV intestinal disease and 3 definitions for CMV reactivation. Prevalence numbers depend on used definition, studied population and region. The highest prevalence for CMV infection was found when using positive serum PCR as a definition, whereas for CMV intestinal disease this applies to the use of tissue PCR > 10 copies/mg tissue. Most patients with CMV infection and intestinal disease had steroid refractory disease and came from East Asia.CONCLUSION: We detected multiple different definitions used for CMV infection and intestinal disease in IBD patients, which has an effect on prevalence numbers and eventually on outcome in different trials. | Tessa EH Römkens Geert J Bulte Loes HC Nissen Joost PH Drenth | 2016 | World Journal of Gastroenterology2016，22，3： | 6 |
| 7 | Management of refractory ascites in cirrhosis:Are we out of date?显示文摘Cirrhosis is a major cause of morbidity and mortality worldwide with liver transplantations as it only possible cure.In the face of a significant organ shortage many patients die waiting.A major complication of cirrhosis is the development of portal hypertension and ascites.The management of ascites has barely evolved over the last hundred years and includes only a few milestones in our treatment approach,but has overall significantly improved patient morbidity and survival.Our mainstay to ascites management includes changes in diet,diuretics,shunt procedures,and large volume paracentesis.The understanding of the pathophysiology of cirrhosis and portal hypertension has significantly improved in the last couple of decades but the changes in ascites management have not seemed to mirror this newer knowledge.We herein review the history of ascites management and discuss some its current limitations. | Alagappan Annamalai Lauren Wisdom Megan Herada Mazen Nourredin Walid Ayoub Vinay Sundaram Andrew Klein Nicholas Nissen | 2016 | World Journal of Hepatology2016，8，28： | 4 |
| 8 | Clinical outcome after orbital floor fracture reduction with special regard to patient's satisfaction显示文摘Purpose: Primary reconstruction via transconjunctival approach is a standardized treatment option for orbital floor fractures. The aim of this study was to compare the findings of specific ophthalmologic assessment with the patient's complaints after fracture reduction. Methods: A retrospective medical chart analysis was performed on patients who had undergone transconjunctival orbital floor fracture reduction for fracture therapy with resorbable foil (ethisorb sheet or polydioxanone foil). A follow-up assessment including ophthalmological evaluation regarding visual acuity (eye chart projector), binocular visual field screening (Bagolini striated glasses test) and diplopia (cover test, Hess screen test) was conducted. Additionally, a questionnaire was performed to assess patients' satisfaction. Results: A total of 53 patients with a mean follow-up of 23 months (ranging from 11 to 72) after surgical therapy were included. Diplopia was present preoperatively in 23 (43.4%) and reduced in follow-up examination (n = 12, 22.6%). Limitations in ocular motility reduced from 37.7% to 7.5%. The questionnaire about the patient's satisfaction revealed excellent outcomes in relation to the functional and esthetical parameters. Conclusion: Transconjunctival approach is a safe approach for orbital fracture therapy. Postoperative diplopia is nearly never perceptible for the individual and differs to pathologic findings in the ophthalmic assessment. | Stefan Hartwig Marie-Christine Nissen Jan Oliver Voss Christian Doll Nicolai Adolphs Max Heiland Jan Dirk Raguse | 2019 | Chinese Journal of Traumatology2019，22，3： | 2 |
| 9 | VEGF mediates angiogenic activity during the priliferative phase of wound healing显示文摘 | Nissen NN Polverini PJ Koch AE | 1998 | Am J Pathol1998，152，6： | 2 |
| 10 | 大鼠胚胎视网膜前体细胞的分离、体外培养及鉴定显示文摘目的探讨流式细胞分析技术、免疫荧光及3HThymidine分析对大鼠胚胎视网膜前体细胞性质及其体外增殖进行鉴定的可行性。方法来源于19d胚胎大鼠视网膜的视网膜前体细胞,使用流式细胞分析及免疫荧光技术从数量及形态上对细胞性质进行鉴定。采用无血清培养基体外培养,通过3HThymidine分析、形态学观察及统计学分析,研究细胞增殖情况。结果从胚胎大鼠全层视网膜分离出的原代视网膜前体细胞,流式细胞分析结果显示:培养0d时,22.23%的细胞神经上皮干细胞蛋白(Nestin)呈阳性表达,16.04%的细胞Sox2呈阳性表达,19.66%的细胞钙结合蛋白呈阳性表达,其余终末视网膜细胞标记物(胶质纤维酸性蛋白、CD90、视紫红质、C反应蛋白、突触前膜列阵蛋白)均呈极微量阳性或阴性。免疫荧光结果显示大部分细胞及细胞球(>90%)Nestin呈阳性表达。培养6d后,流式细胞分析显示43.36%的细胞Nestin阳性,免疫荧光显示Nestin及胶质纤维酸性蛋白呈阳性。连续4d3HThymidine分析及形态学观察、统计学分析原代视网膜前体细胞初期增殖良好。结论流式细胞分析、免疫荧光及3HThymidine等免疫学技术可很好的对视网膜前体细胞性质及其增殖情况进行鉴定。大鼠胚胎原代视网膜前体细胞表现出神经干细胞的特性,根据检测手段不同,阳性结果不同,其原代视网膜前体细胞体外培养初期增殖良好。 | 杨静 Mogens Holst Nissen 王薇 | 2006 | 中华眼科杂志2006，42，2： | 2 |
| 11 | Determination of the degree of hydrolysis of food protein hydrolysates by trinitrobenzenesulfonic acid 显示文摘 | ADLER - NISSEN J | 1979 | J Argric Food Chem1979，27，6： | 1 |
| 12 | Ultrastructure studies on the invasion of melanomas in initial lymphatics skin 显示文摘 | Lubach D Nissen S | 1992 | J Invest Demoatol1992，98，： | 1 |
| 13 | Nutritional role of the leucine metabolite-hydroxy-methylbutyrate (HMB)显示文摘 | NISSEN S L ABUMRAD N N | 1997 | Journal of Biochem Nutrition1997，8，： | 1 |
| 14 | Americancollege of cardiology clinical expert consensus documents显示文摘 | MINTZ G S NISSEN S E ANDERSON W D | 2001 | JAm Coll Cardiol2001，37，5： | 1 |
| 15 | Measurement of 3-methylhistdine production in lambs by using copmpartmental-kinetic analysis显示文摘 | Rathmacher J A Link G S Nissen | 1993 | Brit J Nutri1993，69，： | 1 |
| 16 | Optimum inventory and product quality control with deterministic and stochastic deterioration-An application of distributed parameters control systems显示文摘 | Bensoussan A Nissen G Tapiero C | 1975 | IEEE Trans on Automatic Control1975，20，3： | 1 |
| 17 | Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease显示文摘 | Nissen S E Tuzcu E M Schoenhagen P | 2005 | N Engl J Med2005，352，1： | 1 |
| 18 | Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus 显示文摘 | Nissen S E Wolski K Topoi E J | 2005 | J Am Med Assoc2005，294，20： | 1 |
| 19 | Effect of rosiglitazone on the risk ofmyocardial infarction and death from cardiovascularcauses显示文摘 | Nissen SE Wolski K | 2007 | N Engl J Med2007，356，24： | 1 |
| 20 | The busiest of all ribosomal assistants:elongation factor Tu显示文摘 | Kavaliauskas D Nissen P Knudsen C R | | 0，，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员